A controversial proposal to expand access to peptides—compounds typically restricted by the FDA—has surfaced as the agency prepares to submit an "interim access policy" to the White House for review. The move, disclosed in a recent government filing, could allow compounding pharmacies to temporarily produce and distribute peptides that have historically faced regulatory barriers. Critics and advocates alike are closely watching the potential shift, which may reshape how certain treatments reach patients outside traditional approval channels. The policy’s implications for drug safety and alternative therapies remain a key point of debate.
Presented by Coalition to Strengthen America’s Healthcare {beacon} Healthcare Healthcare The Big Story RFK Jr. advances peptide push The Food and Drug Administration (FDA) this week submitted a peptide “interim access policy” to the White House for review, according to a government filing, which would reportedly allow compounding pharmacies to temporarily produce and sell previously restricted...
